Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Esophagus is commonly affected in Systemic Sclerosis (SSc) and esophageal function is
compromised in about 75% of patients. Previous studies have shown that buspirone, an orally
available 5-HT1A (serotonin 1a receptor agonist), enhances esophageal motility in healthy
volunteers. Recently, the investigators observed that a single dose of buspirone (10mg)
improves lower esophageal sphincter (LES) function in patients with SSc and esophageal
involvement .
Objectives: To evaluate the effect of continuous administration of buspirone on esophageal
dysfunction and related symptoms in SSc using high resolution manometry (HRM).
Phase:
Early Phase 1
Details
Lead Sponsor:
Laikon General District Hospital, Athens Laikο General Hospital, Athens